Ovarian cancer is a heterogeneous disease, making it difficult to provide standard regimens that are effective for all patients. Can increases in long-term survival be achieved by translating recent insights at the molecular and cellular levels into individual strategies for treatment and optimal early detection?
- Robert C. Bast Jr
- Bryan Hennessy
- Gordon B. Mills